A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Alentis Therapeutics AG
Alentis Therapeutics AG
Neonc Technologies, Inc.
Terremoto Biosciences Inc.
Merus B.V.
Radiopharm Theranostics, Ltd
DualityBio Inc.
Yuhan Corporation
Rapa Therapeutics LLC
AP Biosciences Inc.
Jacobio Pharmaceuticals Co., Ltd.
Shanghai Junshi Bioscience Co., Ltd.